Coherus Oncology/$CHRS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Coherus Oncology
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
Ticker
$CHRS
Sector
Primary listing
Employees
147
Headquarters
Website
Coherus Oncology Metrics
BasicAdvanced
$253M
1.18
$1.43
1.09
-
Price and volume
Market cap
$253M
Beta
1.09
52-week high
$2.62
52-week low
$0.71
Average daily volume
1.9M
Financial strength
Current ratio
1.472
Quick ratio
1.357
Long term debt to equity
86.105
Total debt to equity
89.101
Interest coverage (TTM)
-19.60%
Profitability
EBITDA (TTM)
-172.51
Gross margin (TTM)
67.24%
Net profit margin (TTM)
398.43%
Operating margin (TTM)
-418.37%
Revenue per employee (TTM)
$290,000
Management effectiveness
Return on assets (TTM)
-31.20%
Return on equity (TTM)
516.02%
Valuation
Price to earnings (TTM)
1.178
Price to revenue (TTM)
4.694
Price to book
3.36
Price to tangible book (TTM)
13.86
Price to free cash flow (TTM)
-1.311
Free cash flow yield (TTM)
-76.28%
Free cash flow per share (TTM)
-1.289
Growth
Revenue change (TTM)
59.81%
Earnings per share change (TTM)
476.38%
3-year revenue growth (CAGR)
-41.54%
10-year revenue growth (CAGR)
3.45%
3-year earnings per share growth (CAGR)
-27.47%
10-year earnings per share growth (CAGR)
-13.35%
What the Analysts think about Coherus Oncology
Analyst ratings (Buy, Hold, Sell) for Coherus Oncology stock.
Coherus Oncology Financial Performance
Revenues and expenses
Coherus Oncology Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Coherus Oncology stock?
Coherus Oncology (CHRS) has a market cap of $253M as of March 13, 2026.
What is the P/E ratio for Coherus Oncology stock?
The price to earnings (P/E) ratio for Coherus Oncology (CHRS) stock is 1.18 as of March 13, 2026.
Does Coherus Oncology stock pay dividends?
No, Coherus Oncology (CHRS) stock does not pay dividends to its shareholders as of March 13, 2026.
When is the next Coherus Oncology dividend payment date?
Coherus Oncology (CHRS) stock does not pay dividends to its shareholders.
What is the beta indicator for Coherus Oncology?
Coherus Oncology (CHRS) has a beta rating of 1.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.